Full Year 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript

May 22, 2026 / 01:00PM GMT

Release Date Price: ₹1840.7 (-2.67%)

Transcript

Key Points

Positve

Sun Pharmaceuticals Industries Ltd (BOM:524715) reported a 13.6% increase in sales for Q4 FY26 compared to Q4 FY25, reaching INR1,45,598 million.
The company's Global Innovative Medicine sales grew by 20.1% in Q4 FY26, driven by products like Ilumya, Odomzo, Cequa, and Winlevi.
India formulations sales increased by 14.8% in Q4 FY26, with Sun Pharma maintaining its position as the number one company in the Indian pharmaceutical market.
The company declared a final dividend of INR5 per share for FY26, maintaining a total dividend of INR16 per share for the year.
Sun Pharmaceuticals Industries Ltd (BOM:524715) has a strong balance sheet with a net cash position of $3.2 billion at the consolidated level.

Negative

EBITDA margin for Q4 FY26 decreased to 27.1% from 28.7% in Q4 FY25 and 31.9% in Q3 FY26, due to lower milestone income and increased spending in certain geographies.
US sales declined by 1.1% in Q4 FY26, with the generic business facing challenges due to increased competition.
The effective tax rate for Q4 FY26 increased to 22.3% from 19.8% in Q4 FY25.
The company faces ongoing compliance issues affecting its generics business, impacting new product approvals.
Sun Pharmaceuticals Industries Ltd (BOM:524715) anticipates only high single-digit consolidated top-line growth for FY27, indicating potential challenges in maintaining higher growth rates.

Operator

Ladies and gentlemen, good day, and welcome to the Sun Pharma's Q4 FY26 financial results conference call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Dr. Abhishek Sharma, Vice President and Head of Investor Relations and Strategic Projects. Thank you, and over to you, sir.

Abhishek Sharma

Sun Pharmaceutical Industries Ltd - Investor Relations

Thank you. Good evening, and a warm welcome to our fourth quarter and full year FY26 earnings call. I'm Abhishek from the Sun Pharma Investor Relations team. We hope you received the Q4 financials, the press release and the earnings presentation that was sent out earlier in the day. These are also available on our website.

We have with us today Mr. Dilip Shanghvi, Chairman; Mr. Kirti Ganorkar, Managing Director; Mr. Aalok Shanghvi, Chief Operating Officer; Ms. Jayashree Satagopan, CFO; and Mr. Richard Ascroft, CEO, North America.

Today, the team will provide an update on financial performance and business highlights for the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.